Physician profile
Eugene Valsky
NPI 1255398475
$5,833.49
in general payments reported to CMS, 2019-2025
32 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $706 · 2021: $751 · 2022: $922 · 2023: $481 · 2024: $931 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $710.33 | 2019-2025 | |
| Pfizer INC. | $601.63 | 2019-2025 | |
| Amgen INC. | $580.06 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $545.49 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $483.85 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $462.75 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $327.92 | 2019-2025 | Watchman Flx |
| Heartflow, INC. | $263.99 | 2023-2025 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $235.80 | 2019-2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $201.12 | 2021-2025 | Onpattro, Amvuttra |
| Novo Nordisk INC | $189.89 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $163.84 | 2019-2025 | Verquvo |
| Esperion Therapeutics, INC. | $156.55 | 2020-2022 | |
| Amarin Pharma, INC. | $134.98 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.93 | 2021-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $94.20 | 2019-2020 | |
| Abbott Laboratories | $85.87 | 2024-2025 | Cardiomems, Amplatzer Amulet |
| Scpharmaceuticals INC. | $55.18 | 2025 | |
| Sanofi-Aventis U.S. LLC | $51.62 | 2019 | |
| Bridgebio Pharma, INC. | $48.61 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.79 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $39.64 | 2024 | Arcalyst |
| Gilead Sciences, INC. | $38.41 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $31.80 | 2025 | Opsumit |
| Chiesi USA, INC. | $26.50 | 2025 | Juxtapid |
| Lexicon Pharmaceuticals, INC. | $25.84 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $24.02 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.88 | 2022 | |
| Medtronic, INC. | $22.47 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $20.79 | 2019 | |
| Bardy Diagnostics, INC. | $20.00 | 2020 | |
| Medtronic Vascular, INC. | $18.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Valsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.